转移性乳腺癌的疗效监测:18F-FDG PET/CT与常规CT的前瞻性比较研究
该前瞻性研究纳入87例活检证实的转移性乳腺癌女性,每9-12周同时行增强CT和18F-FDG PET/CT监测一线治疗反应,临床决策仅依据增强CT及RECIST 1.1。结果显示18F-FDG PET/CT在43例(49.4%)中首先检出进展,增强CT仅1例(1.15%)首先检出(P<0.0001);PET/CT检出进展至CT检出进展的中位时间为6个月(95%CI 4.3-6.4个月)。
要点
- 18F-FDG PET/CT在49.4%(43/87)患者中首先检出进展,增强CT仅1.15%(1/87)首先检出(P<0.0001)。
- 排除32例无进展患者后,78.2%(43/55)患者由PET/CT首先检出进展。
- PET/CT检出进展至CT检出进展的中位时间为6个月(95%CI 4.3-6.4个月)。
核心结论
- 多数患者中18F-FDG PET/CT较增强CT更早检出疾病进展,增强CT中位延迟6个月,可能具有临床相关性。
- 按PERCIST标准有可测量病灶的患者数多于按RECIST 1.1标准。
- 患者最终获益的幅度是未来研究的方向。
研究设计与样本
- 前瞻性纳入活检证实的转移性乳腺癌女性,每9-12周同时行增强CT和18F-FDG PET/CT监测一线治疗反应。
- 临床决策仅依据增强CT及RECIST 1.1,研究完成时揭盲18F-FDG PET/CT并按PERCIST评估,反应标准不适用时采用视觉评估。
- 共87例可评估,中位随访扫描6次(范围1-11次)。
主要发现
- 18F-FDG PET/CT首先检出进展43/87例(49.4%),增强CT首先检出1/87例(1.15%),P<0.0001。
- 排除无进展患者32例后,18F-FDG PET/CT首先检出进展43/55例(78.2%)。
- PET/CT检出进展至CT检出进展的中位时间为6个月(95%CI 4.3-6.4个月)。
- 基线时按PERCIST有可测量病灶76/87例(87.4%),按RECIST 1.1有可测量病灶51/87例(58.6%)。
- 18F-FDG PET/CT对疗效随时间变化的可视化更优。
关键数值与推荐
- 疗效评估采用RECIST 1.1(增强CT)和PERCIST(18F-FDG PET/CT),反应标准不适用时采用视觉评估。
临床怎么用
- 原文未据此给出推荐。
局限性
- 患者最终获益的幅度是未来研究的方向。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study aimed to compare contrast-enhanced CT (CE-CT) and 18F-FDG PET/CT for response monitoring in metastatic breast cancer using the standardized response evaluation criteria RECIST 1.1 and PERCIST. The objective was to examine whether progressive disease was detected systematically earlier by one of the modalities. Methods: Women with biopsy-verified metastatic breast cancer were enrolled prospectively and monitored using combined CE-CT and 18F-FDG PET/CT every 9-12 wk to evaluate response to first-line treatment. CE-CT scans and RECIST 1.1 were used for clinical decision-making without accessing the 18F-FDG PET/CT scans. At study completion, 18F-FDG PET/CT scans were unmasked and assessed according to PERCIST. Visual assessment was used if response criteria could not be applied. The modality-specific time to progression was defined as the time from the baseline scan until the first scan demonstrating progression. Paired comparative analyses for CE-CT versus 18F-FDG PET/CT were applied, and the primary endpoint was earlier detection of progression by one modality. Secondary endpoints were time to detection of progression, response categorization, visualization of changes in response over time, and measurable disease according to RECIST and PERCIST. Results: In total, 87 women were evaluable, with a median of 6 (1-11) follow-up scans. Progression was detected first by 18F-FDG PET/CT in 43 (49.4%) of 87 patients and first by CE-CT in 1 (1.15%) of 87 patients (P < 0.0001). Excluding patients without progression (n = 32), progression was seen first on 18F-FDG PET/CT in 78.2% (43/55) of patients. The median time from detection of progression by 18F-FDG PET/CT to that of CE-CT was 6 mo (95% CI, 4.3-6.4 mo). At baseline, 76 (87.4%) of 87 patients had measurable disease according to PERCIST and 51 (58.6%) of 87 patients had measurable disease according to RECIST 1.1. Moreover, 18F-FDG PET/CT provided improved visualization of changes in response over time, as seen in the graphical abstract. Conclusion: Disease progression was detected earlier by 18F-FDG PET/CT than by CE-CT in most patients, with a potentially clinically relevant median 6-mo delay for CE-CT. More patients had measurable disease according to PERCIST than according to RECIST 1.1. The magnitude of the final benefit for patients is a perspective for future research.
引用
- Vogsen M, Harbo F, Jakobsen NM, et al. Response Monitoring in Metastatic Breast Cancer: A Prospective Study Comparing 18F-FDG PET/CT with Conventional CT. J Nucl Med. 2022. PMID: 36207136. doi:10.2967/jnumed.121.263358
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。